Tetracaine & Oxymetazoline comment watch save
BreastfeedingGeriatricPediatric

  • FDA APPROVAL DATE: 06/29/2016
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    Beta blockers, MAO inhibitors, Other intranasal products, Tricyclic antidepressants
  • PREGNANCY: Insufficient evidence to inform drug-associated risk

For intranasal use only. See separate entry for oxymetazoline as topical formulation.

Please login to view the rest of this drug profile.

Page last updated 07/31/2023

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top